New evidence of H1-receptor independent COX-2 inhibition by fexofenadine HCl in vitro

Pharmacology

Volumn 78, Issue 3, 2006, Pages 129-135

  Juergens, Uwe R ^a   Gillissen, Adrian ^b   Uen, Sakir ^a   Racké, Kurt ^c   Stöber, Meinolf ^a   Darlath, Wilfried ^d   Vetter, Hans ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Robert Koch Klinik   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Allergic rhinitis; Cyclooxygenase; Fexofenadine; Loratadine

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ANTIHISTAMINIC AGENT; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FEXOFENADINE; HISTAMINE H2 RECEPTOR; LORATADINE; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; TERFENADINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; INCUBATION TIME; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; DOSE RESPONSE; HUMAN; SHEEP;

ANIMALS; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTAMINE H1 ANTAGONISTS; HUMANS; SHEEP; TERFENADINE;

EID: 33751085620     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096016     Document Type: Article

References (38)

1. 1-antihistamines. N Engl J Med 2004;351:2203-2217.
2. MacGlashan D Jr: Histamine: a mediator of inflammation. J Allergy Clin Immunol 2003;112(suppl):S53-S59.
3. Akdis CA, Blaser K: Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003;112:15-22.
4. White M, Kaliner M: Mediators of allergic rhinitis. J Allergy Clin Immunol 1992;90:699-704.
5. Naclerio RM: Pathophysiology of perennial allergic rhinitis. Allergy 1997;52(suppl):7-13.
6. 3 receptors. Clin Exp Allergy 2004;34:456-459.
7. 3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am J Rhinol 1999;13:391-399.
8. White MV, Kaliner MA: Mediators of allergic rhinitis. J Allergy Clin Immunol 1992;90:699-704.
9. McAdam BF, Mardini IA, Habib A, Burke A, Lawson JA, Kapoor S, FitzGerald GA: Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 2000;105:1473-1482.
10. 2 as a mediator of allergic asthma. Science 2000;287:2013-2017.
11. Shi HZ, Sun JJ, Pan HL, Lu JQ, Zhang JL, Jiang JD: Alterations of T-lymphocyte subsets, soluble IL-2 receptor, and IgE in peripheral blood of children with acute asthma attacks. J Allergy Clin Immunol 1999;103:388-394.
12. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
13. Smith WL: Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992;263:F181-F191.
14. Oguma T, Asano K, Shiomi T, Fukunaga K, Suzuki Y, Nakamura M, Matsubara H, Sheldon HK, Haley KJ, Lilly CM, Drazen JM, Yamaguchi K: Cyclooxygenase-2 expression during allergic inflammation in guinea-pig lungs. Am J Respir Crit Care Med 2002;165:382-386.
15. Lundgren JD, Shelhamer JH: Pathogenesis of airway mucus hypersecretion. J Allergy Clin Immunol 1990;85:399-417.
16. Peters-Golden M: Open mind, open airways: broadening the paradigm of prostaglandins and allergic airway inflammation. Am J Respir Crit Care Med 2002;165:1035-1036.
17. Juergens UR, Darlath W, Stober M, Racke K, Tasci S, Gillissen A, Vetter H: Differential effects of fexofenadine on arachidonic acid metabolism in cultured human monocytes. Pharmacology 2006;76:40-45.
18. Niki H, Tominaga Y, Watanabe-Kobayashi M, Mue S, Ohuchi K: Possible participation of cyclooxygenase-2 in the recurrence of allergic inflammation in rats. Eur J Pharmacol 1997;320:193-200.
19. Ouellet M, Falgueyret JP, Percival MD: Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms. Biochem J 2004;377:675-684.
20. Shahab R, Phillips DE, Jones AS: Prostaglandins, leukotrienes and perennial rhinitis. J Laryngol Otol 2004;118:500-507.
21. Carey MA, Germolec DR, Langenbach R, Zeldin DC: Cyclooxygenase enzymes in allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids 2003;69:157-162.
22. Szczeklik A, Stevenson DD: Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999;104:5-13.
23. Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodriguez R, Alfaya T, Iscar A: Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002;121:1812-1817.
24. Takechi M: Combination treatment using the COX-2 inhibitor meloxicam and an antiallergic in pollinosis. J Int Med Res 2004;32:655-664.
25. Niki H, Yamada M, Yamaki K, Mue S, Ohuchi K: Effects of JTE-522, a specific inhibitor of cyclooxygenase-2, on the recurrence of allergic inflammation in rats. Eur J Pharmacol 1998;344:261-267.
26. Asano K, Kanai K, Suzaki H: Suppressive activity of fexofenadine hydrochloride on the production of eosinophil chemoattractants from human nasal fibroblasts in vitro. Arzneimittelforschung 2004;54:436-443.
27. Asano K, Kanai KI, Suzaki H: Suppressive activity of fexofenadine hydrochloride on metalloproteinase production from nasal fibroblasts in vitro. Clin Exp Allergy 2004;34:1890-1898.
28. Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ: Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998;101:410-420.
29. Asano K, Kanai K, Suzaki H: Suppressive activity of fexofenadine hydrochloride on thymus- and activation-regulated chemokine production from human peripheral blood leukocytes in response to antigenic stimulation in vitro. Int Arch Allergy Immunol 2004;133:267-275.
30. Sakairi T, Suzuki K, Makita S, Wajima T, Shakuto S, Yoshida Y, Yaguchi M: Effects of fexofenadine hydrochloride in a guinea pig model of antigen-induced rhinitis. Pharmacology 2005;75:76-86.
31. Wilson AM, Haggart K, Sims EJ, Lipworth BJ: Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002;32:1504-1509.
32. Van Cauwenberge P, Juniper EF: Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000;30:891-899.
33. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J: Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:927-933.
34. Marshall GD Jr: Therapeutic options in allergic disease: antihistamines as systemic antiallergic agents. J Allergy Clin Immunol 2000;106(suppl):S303- S309.
35. Agrawal DK: Anti-inflammatory properties of desloratadine. Clin Exp Allergy 2004;34:1342-1348.
36. 1 receptor. Int Arch Allergy Immunol 2004;135:313-318.
37. Yang CM, Chien CS, Hsiao LD, Luo SF, Wang CC: Interleukin-1β-induced cyclooxygenase-2 expression is mediated through activation of p42/44 and p38 MAPKS, and NF-κB pathways in canine tracheal smooth muscle cells. Cell Signal 2002;14:899-911.
38. Chacon P, Vega A, Monteseirin J, Bekay RE, Alba G, Perez-Formoso JL, Msartinez A, Asturias JA, Perez-Cano R, Conde J: Induction of cyclooxygenase-2 expression by allergens in lymphocytes from allergic patients. Eur J Immunol 2005;35:2313-2324.